Zhancheng Bio Completes Pre-A Financing to Build a Leading Domestic Primary Healthcare Supply Chain

VCBeat has learned that Hebei Zhancheng Biotechnology Co., Ltd. (hereinafter referred to as “Zhancheng Bio”) announced the completion of its Pre-A round of financing, with investors including Beijing Yuefeng Capital, Tianjin Chongyi Capital, and Fanzhi Yunlian, a pharmaceutical ecosystem platform. The funds raised in this round will be primarily used to enhance the product line for primary healthcare supply chains and establish a comprehensive warehousing and distribution network.

Zhancheng Biologics, established in 2017, is a biologics enterprise committed to advancing China’s disease prevention initiatives. Leveraging the dissemination of the latest information on “prophylactic biological products” and national prevention and control policies, the company takes it as its mission to continuously provide “products that promote and safeguard public health.” It is a leading enterprise in Hebei Province’s primary healthcare service system.

The company’s business spans multiple sectors, including vaccine promotion, blood products promotion, medical devices, medical consumables, and clinical laboratory services. Its marketing network covers over 90% of the counties and districts in Hebei Province. The company is committed to building a leading primary healthcare supply chain in China, thereby supporting the nation’s efforts to establish a more robust basic medical service system.

Company founder, Zhanfeng Zhen,Former Sales Director for Hebei Province at a leading domestic vaccine and blood products company, with 11 years of experience in promoting vaccines and protein-based products in Hebei Province. Possesses extensive expertise in vaccine sales and marketing, with a professional network covering CDC clients at the provincial, municipal, and county/district levels in Hebei Province.

Co-founder Wang Cheng, holds a degree in Preventive Medicine. Previously served as a physician at the Panjin Center for Disease Control and Prevention in Liaoning Province, Marketing Manager at a domestic rabies vaccine manufacturer, and Marketing Director at a leading Chinese enterprise specializing in vaccine and blood product sales. During his tenure, he was responsible for national market operations and management, demonstrating professional expertise in market planning and academic promotion.

The company currently has nearly 100 employees, with its marketing network coveringHebei Province's 156 Districts and Counties(173 valid districts and counties in Hebei Province),Serves over 1,100 outpatient clinics.

The company adheres to an “academic promotion” strategy, engaging numerous national and provincial experts from institutions such as the Academy of Military Medical Sciences, the Chinese Preventive Medicine Association, the Chinese Center for Disease Control and Prevention (China CDC), and the Hebei Provincial Center for Disease Control and Prevention to provide academic guidance. By leveraging scenarios including departmental meetings, clinical observation visits, and home visits, the company enhances the social value of its “co-branded vaccines,” thereby promoting the effective use of its products.

Zhanfeng Zhen, Founder and Chairman of Zhancheng BiologyIt indicates that while the health concept of prioritizing treatment over prevention has been prevalent in China, the onset of the COVID-19 pandemic and the public’s growing awareness of disease prevention and management have gradually ingrained the idea of vaccination as a preventive measure. Consequently, there is an increasingly strong demand among the public for receiving vaccinations, managing mild symptoms, and handling chronic diseases at primary healthcare institutions. As all our products and services are centered around this need, the industry boasts broad prospects for development.

Wang Cheng, Co-founder and General Manager of Zhancheng BiotechStatement: Zhancheng Biotechnology remains committed to disseminating the latest information on “prophylactic biological products” and national prevention and control policies, taking it as its responsibility to continuously provide products that promote and safeguard public health. Closely aligned with the needs of primary healthcare institutions and the general public, the company deeply cultivates the primary healthcare supply chain, constantly enhances its product portfolio and channel resources, and is dedicated to delivering safe, timely, and comprehensive preventive and diagnostic services to the broader population.

Ma Yanlong, Founder of Yuefeng Capital and Chairman, a Returned Overseas Chinese EntrepreneurIt stated: The development of primary healthcare infrastructure holds immense strategic significance at the national level in China and is a core element in achieving common prosperity for all. We are optimistic about Zhancheng Biology’s founding team, given their extensive expertise and experience in grassroots medical services. By providing services to the general public in areas such as vaccines and medical devices, they address a vast market with profound societal impact. Yuefeng Capital is committed to continuously identifying value-driven entrepreneurs and supporting their growth.

Dr. Song Keqing, Chairman of the Fanzhi Yunlian Pharmaceutical Ecosystem Enterprise PlatformIt stated: “Fanzhi Yunlian,” a pharmaceutical ecosystem platform, has been committed to the coordinated development of enterprises within the pharmaceutical ecosystem. By controlling and integrating products, supply chains, and channels, it has basically achieved the strategic capability to compete with top-tier international brands and possess unique innovative competitive advantages. We also remain optimistic about the long-term development of healthcare service systems based on terminal coverage. The founding team of Zhancheng Biotechnology possesses successful commercialization and marketing experience. Leveraging their refined control over preventive care products and precise management of distribution channels, they are poised to drive the advancement of China’s primary healthcare service system.

Yuefeng Capital is an investment platform co-founded by senior executives of publicly listed companies, seasoned entrepreneurs, and international supply chain experts. Its early partners comprise experts from diverse fields, including overseas-educated scientists, executives of publicly listed companies, and angel investors. The firm is dedicated to value investing in and empowering startups with strong technological attributes and significant potential industrial influence in the sectors of intelligent manufacturing, pharmaceuticals and healthcare, and new energy.

Chongyi Capital, established in the Tianjin Free Trade Zone, is an investment platform co-founded by executives of listed companies and senior technology experts. The founders possess extensive experience in entrepreneurship within frontier technology-based real industries, as well as in financing, investment, and mergers and acquisitions. Dedicated to the long-term incubation of strategic emerging industries such as biomedicine, intelligent manufacturing, and integrated circuits, Chongyi Capital supports projects aimed at overcoming key core technologies and addressing critical bottlenecks (“chokepoint” areas). By providing multidimensional resources—including capital, industry connections, and market access—the firm empowers enterprises and accompanies their long-term growth.

Fanzhi Yunlian is China’s leading industrial-grade biopharmaceutical ecosystem platform (hereinafter referred to as “Fanzhi Yunlian Biopharmaceutical Ecosystem”). Spearheaded by Beijing Fanzhi Medical Technology Co., Ltd. and built upon years of deep industry engagement, the platform leverages mechanisms such as foundational technology empowerment, resource synergy, and equity cooperation to bring together dozens of Chinese scientists, overseas-returnee scientists, and entrepreneurs. Together, they have established a biopharmaceutical ecosystem consortium featuring fully autonomous and controllable foundational technologies, connecting upstream and downstream enterprises across the industrial chain, and boasting robust capabilities in foundational technology, supply chain, and ecosystem integration. This initiative aims, on one hand, to eliminate bottlenecks and import dependencies related to foundational technologies and core raw materials, and on the other hand, to achieve differentiated competitive advantages over foreign brands through its ecosystem, thereby continuously enhancing its capacity to compete—and potentially gain an edge—in the long-term international arena.

Fanzhi Yunlian Pharmaceutical Ecosystem Chain not only facilitates the development of China’s biopharmaceutical industry but also empowers enterprises within its ecosystem. By fostering an integrated ecosystem encompassing government, industry, academia, research, finance, healthcare, and application, it addresses multidimensional challenges and resource gaps in R&D, entrepreneurship, manufacturing, registration, marketing, financing, and IPOs. This enables scientists and entrepreneurs to pursue innovation with confidence and focus on long-term growth, cultivating more prominent industry brands and helping Chinese pharmaceutical companies compete globally. To date, Fanzhi Yunlian has empowered nearly 100 industry enterprises and established deep partnerships with 30 upstream and downstream companies, including suppliers of protein and antibody raw materials, instruments, chips, diagnostic reagents, and sequencing reagents, as well as downstream providers of pathogenic microorganism testing, single-cell sequencing, gene editing, early screening for blood and urological tumors, and internet healthcare services. Many of these ecosystem enterprises have achieved annual revenues in the hundreds of millions of yuan, completed three to five rounds of financing, and demonstrated potential for mergers and acquisitions or independent IPOs. “Fanzhi Yunlian” has thus begun to establish significant scale and influence.